论文部分内容阅读
目的:探讨白细胞分化抗原CD20表达对成人前B急性淋巴细胞性白血病(Pre B-ALL)临床特征及治疗转归的影响.方法:回顾性分析我院2005-01/2008-01成人前B-ALL患者91例临床特征及治疗转归,比较CD20阳性患者及CD20阴性患者第1疗程诱导治疗完全缓解率、持续完全缓解率、髓外浸润率、复发率及2 a生存率.结果:91例成人前B-ALL患者中CD20阳性患者43例(47%),CD20阴性患者48例(53%);CD20阳性与阴性患者经第1疗程诱导治疗后获完全缓解率分别为69.8%(30/43),81.3%(39/48)(P>0.05),持续完全缓解率分别为11.6%(5/43),41.7%(20/48)(P<0.05);髓外浸润率分别为46.5%(20/43),22.9%(11/48)(P<0.05);复发率分别为65.1%(28/43),39.6%(19/48)(P<0.05);2 a总生存率分别为17.3%,47.2%(P<0.05).结论:成人Pre B-ALL瘤细胞表达CD20提示预后不良.
Objective: To investigate the effect of leukocyte differentiation antigen (CD20) expression on the clinical features and prognosis of pre-B acute lymphoblastic leukemia in adults before and after treatment.Methods: ALL patients with clinical features and treatment outcome of 91 cases, CD20-positive patients and CD20-negative patients treated with induction of complete remission rate, sustained complete remission rate, extramedullary infiltration rate, recurrence rate and 2-year survival rate.Results: 91 cases In pre-adult B-ALL patients, 43 patients (47%) were CD20-positive patients and 48 patients (53%) were CD20-negative patients. The complete remission rates of CD20-positive and negative patients after treatment with the first course were 69.8% (P <0.05). The rates of sustained complete remission were 11.6% (5/43) and 41.7% (20/48) respectively (P <0.05), and the extramedullary infiltration rates were 46.5 The recurrence rates were 65.1% (28/43) and 39.6% (19/48), respectively (P <0.05). The overall survival rate of 2-year Respectively, 17.3% and 47.2%, respectively (P <0.05) .Conclusion: The expression of CD20 in adult Pre B-ALL tumor cells suggests a poor prognosis.